From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 16:02:08 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD - Washington Times Corona virus interviw
Attachments: RE: Interview request: Wuhan coronavirus, Washington Times
Thank you. Would like to film for both our radio and social media (Facebook and Youtube). Looking forward to hearing from you.

Carmen Wu
Broadcaster
Cantonese Service

Radio Free Asia
2025 M Street NW Ste. 300
Washington, DC 20036
Telephone - (202) 530-4016
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 17:38:31 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD- ABC local news Corona on Camera (Taped)
Attachments: RE: Media Request: Wuhan coronavirus/ABC7 TV (in office, on camera)
My name is Stacia Brown, and I'm a producer for NPR's daily news show, 1A. I'm writing to see if you might be able to join us for an on-air discussion about the coronavirus tomorrow. We're planning a "latest updates" and fact-check conversation for a 10:30 - 11am segment tomorrow, January 28. If you'd be able to join us in studio at WAMU on American University's campus, we'd be honored to have you back as a guest.

Thank you for considering this request!

Sincerely,

Stacia Brown
Producer, 1A
WAMU 88.5 | 4401 Connecticut Ave NW, Washington, DC 20008
202.885.1296 (o)
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 17:54:26 +0000
To: Fauci, Anthony (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: Pre-Brief: GPMB Mtg w/ Nicki Lurie & Jerry Keusch
Attachments: RE: time to discuss GPMB, RE: time to discuss GPMB
Andrew Verdugo - on site contact Cell is (b) (6) — CALL ANDREW UPON ARRIVAL AND HE WILL MEET IN LOBBY.
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 18:13:03 +0000
To: Fauci, Anthony (NIH/NIAID) [E]; Awwad, David (NIH/NIAID) [C]
Subject: NewsMax Live Hit 7:20 pm ET - 7:30 pm ET
Attachments: RE: Wuhan interview with Dr. Fauci
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 14:33:19 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Interview with WIRED re Coronavirus
Attachments: FW: Wired article on Wuhan coronavirus, RE: Wired article on Wuhan coronavirus, RE: Wired article on Wuhan coronavirus, FW: Wired article on Wuhan coronavirus
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 16:51:31 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD CNBC Taped or Live on Camera
Attachments: RE: CNBC
Is there a cell number to reach you? or best number?

Patricia L. Conrad  
Public Health Analyst and  
Special Assistant to the Director  
National Institute of Allergy and Infectious Diseases  
The National Institutes of Health  
31 Center Drive, MSC 2520 - Room 7A03  
Bethesda, Maryland 20892  
301-496-4409 fax

Disclaimer:  
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

I could not make it until 5pm CET today. But next few days also OK.

Dr Fauci is in back to back meetings but hopes to be able to step out and call you between 3:00 pm ET - 4:00 pm ET. Is that time ok and what is the best number to reach you at that time?

Best,
Tony - Would be very keen to hear your personal views on n-CoV. If you have 5 mins for a phone call. Best wishes Jeremy
Mike:

I am sorry but I have an important meeting with Secretary Azar that is a prep meeting for another important meeting at the White House. These overlap with the 19:00 CET time frame of your call. Unless something changes I cannot be on the call. If that is the case, I will ask Hilary Marston from my staff to fill in for me and report back to me. Please send the call in information to my Special Assistant, Patty Conrad, and me just in case something changes.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

From: RYAN, Michael J. <(b) (6)>
Sent: Wednesday, January 29, 2020 10:45 AM
To: Redfield, Robert R. (CDC/OD) (b) (6)
Chris.Elias <(b) (6)>
David Heymann <(b) (6)>
Fauci, Anthony <(b) (6)>
COX, Paul Michael <(b) (6)>
SHOC <shoc@who.int>; GREIN, Thomas <(b) (6)>
GHEBREYESUS, Tedros Adhanom <(b) (6)>
SCHWARTLANDER, Bernhard F. <(b) (6)>
MINHAS, Raman <(b) (6)>
Cc: GHEBREYESUS, Tedros Adhanom <(b) (6)>
SCHWARTLANDER, Bernhard F. <(b) (6)>
MINHAS, Raman <(b) (6)>
Subject: Informal coronavirus teleconference, 29 January, 19.00 CET

Dear colleagues,

Dr Tedros would like to take the opportunity to informally discuss with you the ongoing 2019 novel coronavirus.
We are planning to host a teleconference today at 19.00 CET and will provide a dial-in number with a passcode.

If you face any difficulties with the dial-in number, please provide us with a contact number and we will attempt to dial you in.

Best,

Mike
My cell number is (b) (6). We will add you on Skype tomorrow and contact you with via the username below. Thank you!

The Skype username is (b) (6).

Maranda Finney
The Daily Caller
maranda@dailycaller.com
Topic: Wuhan coronavirus
Deadline: Thursday
Yes, we can confirm for 12:30pm ET for the interview. This will be done by landline and taped on our end.

If you need to reach me the best number is (00) (9)

My name is Shannon Rice, I'm a producer at C-SPAN. Jenn Ruff from Washington Journal passed me on your contact info and says hello! We were hoping that Dr. Fauci might have some time this week to do TAPED podcast on the Coronavirus & disease outbreaks in general. It would be for our podcast The Weekly. It would be 20-25 minutes in length. No calls, just a conversation between him and our host Steve Scully.

We can either do it on the phone or if he is available we can arrange a car for him to come to the studio here on Capitol Hill. Might he have any time this week?

Thank you so much.

Shannon Rice
C-SPAN Radio
Producer, Washington Today & The Weekly Podcast
202-626-4841
Thanks, Francis.

> On Jan 23, 2020, at 8:51 AM, Collins, Francis (NIH/OD) [E] wrote:
> 
> Thanks for all this updated info, Tony. I had a premonition that Lally Weymouth would call on me at the Washington Post luncheon (in front of numerous US Cabinet members, Ivanka, and several heads of state). Sure enough, she did. I think I did a decent job of relating what we currently know about coronavirus, and what we don’t know yet.
> 
> If there are press calls about what the US is doing, I will refer them to you. I’m ceding John.
> 
> FC
> 
> -----Original Message-----
> From: Fauci, Anthony (NIH/NIAID) [E]
> Sent: Thursday, January 23, 2020 6:36 AM
> To: Collins, Francis (NIH/OD) [E]
> Subject: RE: Coronavirus and Davos
> 
> Anecdotal data suggest that most transmissions occur when transmitter is late in the infection, i.e. clinically ill. However, some anecdotal data suggest that early transmission does occur to some degree. The man in Seattle who travelled to Wuhan cannot remember coming into contact with anyone who appeared ill. Regarding mAbs, we have them against SARS and MERS and are hoping that there is some cross-reactivity of the anti-SARS Abs with nCov. However, it is difficult at this time to test since we do not yet have isolates of nCov; we only have sequence. As soon as we get isolates we can test.
> 
> -----Original Message-----
> From: Collins, Francis (NIH/OD) [E]
> Sent: Thursday, January 23, 2020 5:50 AM
> To: Fauci, Anthony (NIH/NIAID) [E]
> Subject: Coronavirus and Davos
> 
> Hi again,
> 
> Was just part of a discussion with Hatchett, Farrar, WHO rep (Tedros not here), Berkley, Stoffels. Big issue seems to be whether transmissibility happens early or late in the course of infection. Obviously late would be much better for public health measures. Your read on current data?
> 
> Any effort on developing MAbs at NIH?
> 
> FC
> 
> Sent from my iPhone
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 13:55:09 +0000
To: Secretary Scheduler (OS/IOS)
Subject: Accepted: HOLD: AMA updates on Coronavirus
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 20:19:37 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD - WTOP Live hit at 12:10 pm ET
Attachments: RE: WTOP Request

Hoping Dr. Fauci can is available is join us tomorrow morning or early afternoon to discuss the WHO declaring a public emergency for the coronavirus.

We could pretape the interview at 8:30am or he could join us live at 10:40a, 11:10a, or 12:10p.

Thanks!

Joslyn Chesson
Editor
WTOP News
(202) 895-5060
Please handle
Sent from my iPhone

Begin forwarded message:

From: [b](6)
Date: January 25, 2020 at 1:39:13 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" [b](6)
Subject: Prospective Intern, Interested in Your Research

Howdy Dr. Anthony S. Fauci,

I have recently completed the SIP application to be considered for a summer internship through the NIH. Upon searching for potential labs to contact I quickly found your name and was intrigued by your work and the potential to be considered as an intern in your research group. I apologize if this is not standard protocol, I definitely feel some apprehension towards reaching out to such esteemed scientists but the recommendation given upon submission of the application was that I reach out to researchers, as you-all are the deciding factor in the placement of interns.

I am a senior Animal Science, Entomology, and Public Health student at [b](6) who will be attending [b](6) as a Masters Student, studying Epidemiology, in the Fall of 2020.

I am very interested in the research interests listed under your profile, specifically concerning your work on understanding the molecular mechanisms of immune dysfunction caused by HIV infection as well as the references to your work, in the news, concerning the Wuhan Coronavirus. [b](6)

I believe a lab such as yours could be beneficial in preparing me for success in these endeavors!

I have spent my undergraduate career working in a CDC Excellence Center lab under [b](6)
I would love to get in contact with you concerning the potential to be involved in your research!

I appreciate your time.
Hello Dr. Fauci -- My name is Tamera, I handle the booking for Newt Gingrich’s Podcast, *Newt’s World*. It is a non-partisan show where Newt gives historical context behind people and events. We launched last February and have 2.5 millions downloads to date with new episodes each Sunday. We are working on an episode of the podcast centered around “The Coronavirus” where you might discuss *The Global viruses* [Novel Coronavirus 2019 (nCoV-2019), SARS, MERS, Bird Flu] and *What Can Be Done to Prevent the Next Epidemic?*

If interested, Newt would interview you on Thursday, February 6th, where you would call in to the studio. The podcast would air Sunday, February 9th.
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 18:57:18 +0000
To: Fauci, Anthony (NIH/NIAID) [E]; Masur, Henry (NIH/CC/CCMD) [E]; Burton, Deborah (NIH/CC/CCMD) [E]; Shyamasundaran Kottilig [b](b); Barasch, Kimberly (NIH/NIAID) [C]; Lerner, Andrea (NIH/NIAID) [E]; Eisinger, Robert (NIH/NIAID) [E]
Subject: Update on HIV, HBV, OUD with Drs Masur and Kottilig
Attachments: RE: Update on HIV, HBV, OUD, Update on HIV, HBV, OUD with Drs Masur and Kottilig

NIH-002495
On Jan 26, 2020, at 3:08 PM, Marston, Hilary (NIH/NIAID) [E] wrote:

From: "Buchholz, Ulla (NIH/NIAID) [E]" <(b)(6)>
Date: Sunday, January 26, 2020 at 1:25 PM
To: Hilary Marston (b)(6)
Cc: "Cohen, Jeffrey (NIH/NIAID) [E]" (b)(6)
Subject: Wuhan coronavirus

Dear Hilary,

In 2003/2004, a small group in the lab of Peter Collins rapidly generated parainfluenza virus vaccine candidates expressing SARS S, please see attached publications. We used a bovine/human parainfluenza virus type 3 vector (B/HPIV3) which contains internal proteins of bovine PIV3; its surface glycoproteins F and HN are derived from human PIV3. In the African green monkey model, a single intranasal dose of B/HPIV3 expressing the S protein of SARS CoV S induced high levels of SARS CoV neutralizing antibodies. After SARS CoV challenge, all control animals shed SARS CoV, while no SARS CoV shedding was detected in the B/HPIV3/SARS-S immunized NHPs.

This vector is also being used to express versions of the respiratory syncytial virus fusion protein. The RSV F expressing version of B/HPIV3 has been evaluated in Phase 1 studies, and shown to be safe in PIV3-seronegative infants and children.
Thank you,
Ulla

Ursula Buchholz, PhD
Senior Associate Scientist
RNA Viruses Section
Laboratory of Infectious Diseases
NIAID, NIH
Bldg. 50, Rm. 6503
50 South Drive, MSC 8007
Bethesda, MD 20892

Phone: (301) 480-1268
Fax: (301) 480-1268
email: 

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.
Erika Esposito (Producer)
RAI Italy
booking@qvgusa.com
Reporter: Claudio Paglira
Subject: coronavirus, ASF profile

Hi Patty,

Italy’s national TV network would like to produce a segment on their evening news broadcast profiling Dr. Fauci’s work on coronavirus and infectious disease control generally. The crew is based in NYC and can come to campus at Dr. Fauci’s earliest convenience anytime after Feb 5. They anticipate needing 30 min for an interview with 20 min for set-up in his office.
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 17:55:17 +0000
To: Fauci, Anthony (NIH/NIAID) [E]; Awwad, David (NIH/NIAID) [C]; Conrad, Patricia (NIH/NIAID) [E]
Subject: HOLD Hill.TV Corona Interview - taped via Skype 1:00 -1:15pm
Attachments: RE: Hill.TV Interview Request, RE: Hill.TV Interview Request
Sent from my iPhone

Begin forwarded message:

From: Ayesha Khan <Aisha.Khan@FOXTV.COM>
Date: January 26, 2020 at 4:53:10 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b)(6)>
Subject: Ayesha from FOX 5

Hello Dr. Fauci,

Reporter Ayesha Khan from FOX 5. Are you by any chance available for another on camera interview regarding three people who are currently being investigated for possibly showing signs of the Coronavirus in Virginia? Two in Central and one in No. Va.

I can be reached on my cell at (b)(6).
Thanks so much!
Ayesha
Wonderful! Thanks for sending.

On Jan 28, 2020, at 11:10 AM, Howard Bauchner <Howard.Bauchner@jamanetwork.org> wrote:

Tony – see below!

Howard Bauchner, MD
Editor in Chief of JAMA and the JAMA Network

Please respect the confidentiality of this email

Listen to my [chats with authors](#)

Late yesterday I had the privilege of interviewing Tony Fauci about the coronavirus epidemic. A follow-up of his VP that we published.

Had 1000 folks listening in while we live streamed it (Mike tells me that is good).

More exciting it has had 70,000 views on the various outlets – see below.

Not sure there is anyone in the world who could provide as erudite a description of SARS, MER, and this new outbreak than Tony.

HCB

From: Eman Aly
Sent: Tuesday, January 28, 2020 9:19 AM
To: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Cc: Michael Berkwits <Michael.Berkwits@jamanetwork.org>
Subject: Links to Livestream

Twitter: [https://www.pscp.tv/w/1vOGwolpLeGB](https://www.pscp.tv/w/1vOGwolpLeGB)

Youtube: [https://www.youtube.com/watch?v=3qlagdc_luM](https://www.youtube.com/watch?v=3qlagdc_luM)

Eman H. Aly
Manager – Social Communications & Digital Channel Strategy
JAMA Network™
330 N Wabash Ave, Ste 39300, Chicago, IL 60611
T 312-464-4259 M (b) (6)
eman.aly@jamanetwork.org
jamanetwork.com
Skype: eman.aly
Twitter: @EmanMSW
Twitter: @JAMANetwork

NIH-002506
Let us discuss.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (301) 496-4409  
FAX: (301) 496-4409  
E-mail: fauci@nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: events@cov-s.com <events@cov-s.com>  
Sent: Wednesday, January 29, 2020 10:38 AM  
To: Fauci, Anthony (NIH/NIAID) [E] <fauci@nih.gov>  
Subject: Coronavirus Preparedness Summit & Workshop- Call for Speakers

Dear Dr. Fauci,

It is my sincere pleasure to invite you to speak at the upcoming Coronavirus Preparedness Summit & Workshop planned for this June 17th to 19th in Washington, DC.

With expected 300 delegates from local, state, federal, and abroad, the 3-day event will bring together Public Health Officials, Emergency Preparedness Leaders, Academia, Business, Public and Private Sector Partners.

The 2019-nCoV Summit will provide a platform for public health officials and community stakeholders to come together, to network and exchange preparedness and response efforts. Special emphasis will be placed on identifying the responsibilities of various stakeholders in order to improve global communication coordination and collaboration.

Topics include:
- Delivery of Vaccine and Antiviral Medication
- Mass Fatality Management Planning
- Preparing Communities Strategies; Local Partnership and Participation
- Benefit-Risk Assessment: Public Health, Industry and Regulatory Perspectives
- Prevention Education Efforts and Risk Communication
- Command, Control and Management

NIH-002507
- Emergency Response Management
- Business-Based Planning
- Community-Based Planning

I greatly appreciate your consideration of this request.

Best Regards,

Edna Santos
(703) 651-2092
events@cov-s.com
Events Coordinator

CORONAVIRUS PREPAREDNESS
SUMMIT & WORKSHOP
WASHINGTON, DC  JUNE 17-19, 2020
Syllabus
11250 Roger Bacon Drive #10, Reston, VA 20190
Thanks

On Jan 28, 2020, at 10:21 AM, Corey MD, Larry <b>(6)</b>wrote:

Interesting email from Davide Corti <b>(4)</b>
Helen how is the patient doing?

Sent from my iPhone

Begin forwarded message:

From: Davide Corti <b>(6)</b>
Date: January 28, 2020 at 7:00:05 AM PST
To: Skip Virgin <b>(6)</b>
Cc: "Corey MD, Larry" <b>(6)
Subject: Re: [EXTERNAL] FW: Patient with coronavirus

Hi!
Thanks for sharing these infos.

Best,
Davide

On Jan 28, 2020, at 5:23 AM, Skip Virgin <b>(6) wrote:
Davide please comment

Skip

Herbert W. 'Skip' Virgin M.D., Ph.D.
Executive Vice President, Research
Chief Scientific Officer
Vir Biotechnology
499 Illinois Avenue
San Francisco CA 94158
he/him/his

From: Corey MD, Larry
Sent: Monday, January 27, 2020 4:49 PM
To: Skip Virgin
Subject: RE: [EXTERNAL] FW: Patient with coronavirus

You are a god

Herbert W. 'Skip' Virgin M.D., Ph.D.
Executive Vice President, Research
Chief Scientific Officer
Vir Biotechnology
499 Illinois Avenue
San Francisco CA 94158
he/him/his

From: Corey MD, Larry
Sent: Monday, January 27, 2020 1:13 PM
To: Skip Virgin, George Scangos
Subject: [EXTERNAL] FW: Patient with coronavirus

From: Helen Y Chu
Sent: Sunday, January 26, 2020 9:11 PM
To: Corey MD, Larry
Cc: Boeckh, Michael
Subject: Re: Patient with coronavirus

Thank you, Larry, understood.

Helen Y. Chu, MD MPH
Division of Allergy & Infectious Diseases
chulab.org
*Our lab has moved to a new location in South Lake Union*

From: "Corey MD, Larry"
Date: Sunday, January 26, 2020 at 1:42 PM
To: Helen Y Chu
Cc: "Boeckh, Michael"
Subject: RE: Patient with coronavirus

Helen
Dear John,
That sounds perfect. We will wait to hear from you about setting up a call as soon as possible.

Helen

---

Great.

Helen – I just talked to Barney who will be out of town next week, but suggested we proceed with a call. Kaitlyn Morabito is coordinating efforts for his lab and our clinical staff now also copied.
So let's wait to get confirmation for Hilary Marson from Tony's office – and then Tina can find time for a call.

John

From: Anna Wald
Sent: Sunday, January 26, 2020 12:56 PM
To: Mascola, John (NIH/VRC) [E]
Cc: Corey MD, Larry <(b)(6)>; Helen Y Chu <(b)(6)>; Julie McElrath <(b)(6)>; Kathleen Neuzil <(b)(6)>; Wesley C. Van Voorhis <(b)(6)>; Graham, Barney (NIH/VRC) [E] <(b)(6)>; Corbett, Kizzmekia (NIH/VRC) [E] <(b)(6)>; Morabito, Kaitlyn (NIH/VRC) [E] <(b)(6)>; Bok, Karin (NIH/VRC) [E] <(b)(6)>; Stein, Judy (NIH/VRC) [C] <(b)(6)>
Subject: Re: Patient with coronavirus

Dear John,

That sounds perfect. While I would like to remain in the loop, I am teaching in subSaharan Africa for the next 2 weeks so calls may be hard to coordinate with my schedule and I don’t want to delay the discussions. Please go ahead and work with Helen directly- I know she is excited to collaborate. Helen and I will talk so she can update me.

Please don’t hesitate to call my cell if there is anything we should discuss.

Best, Anna

Anna Wald, MD, MPH
Head of Allergy and Infectious Diseases Division
Professor of Medicine, Laboratory Medicine &Epidemiology, University of Washington
tel. <(b)(6)>
fax. 206/520-4371
University of Washington Virology Research Clinic
http://depts.washington.edu/herpes/

PHYSICAL LOCATION:
908 Jefferson St, Suite 11NJ-1166, Seattle, WA 98104

MAILING ADDRESS:
Harborview Medical Center, 325 9th Ave, Box #359928, Seattle, WA 98104

Privileged, confidential or patient identifiable information may be contained in this message. This information is meant only for the use of the intended recipients. If you are not the intended recipient, or if the message has been addressed to you in error, do not read, disclose, reproduce, distribute, disseminate or otherwise use this transmission. Instead, please notify the sender by reply e-mail, and then destroy all copies of the message and any attachments.

From: Mascola, John (NIH/VRC) [E] (b) (6)
Sent: Sunday, January 26, 2020 9:49:31 AM
To: Anna Wald (b) (6)
Cc: Corey MD, Larry (b) (6); Helen Y Chu (b) (6); Julie McElrath (b) (6); Kathleen Neuzil (b) (6); Wesley C. Van Voorhis (b) (6); Graham, Barney (NIH/VRC) [E] (b) (6); Corbett, Kizzmekia (NIH/VRC) [E] (b) (6); Morabito, Kaitlyn (NIH/VRC) [E] (b) (6); Bok, Karin (NIH/VRC) [E] (b) (6); Stein, Judy (NIH/VRC) [C] (b) (6)
Subject: RE: Patient with coronavirus

Dear Anna,

Thank you for this important email. We have had discussion with CDC leadership that NIAID/NIH should be primarily involved here. I’m copying the NIH POC, Dr. Hillary Marston, special assistant to Dr. Fauci.

Of note, Dr. Barney Graham and several of his lab are leading our CoV vaccine and antibody efforts. Barney’s lab has been working for several years on CoV spike protein and can produce stabilized versions that can be used as vaccine immunogens and protein probes to isolate antibodies. He is making these available to CDC and others.

Hilary, with help from Karin Bock on our end, can help set up a call, which I suggest would first be between your group and our NIH staff.

Thank you,

John R. Mascola, M.D.
Director, Vaccine Research Center
National Institute of Allergy and Infectious Diseases
National Institutes of Health
email: (b) (6)
office tel: (b) (6)
From: Anna Wald (b) (6)>
Sent: Sunday, January 26, 2020 12:02 PM
To: Mascola, John (NIH/VRC) (E) (b) (6)
Cc: Corey MD, Larry (b) (6); Helen Y Chu (b) (6); Julie McElrath (b) (6); Kathleen Neuzil (b) (6); Wesley C. Van Voorhis (b) (6)

Subject: Patient with coronavirus

Dear Dr. Mascola,

I am heading to the airport in few hours for a trip to Kenya so will not be on email. However, if anyone is trying to reach me, my cell phone is (b) (6).

Thank you, Anna

Anna Wald, MD, MPH
Head of Allergy and Infectious Diseases Division,
Professor of Medicine, Laboratory Medicine & Epidemiology,
University of Washington
tel. 206/520-4340
fax. 206/520-4371
University of Washington Virology Research Clinic
http://depts.washington.edu/herpes/
pronouns: she/her/hers

PHYSICAL LOCATION:
908 Jefferson St, Suite 11NJ-1166, Seattle, WA 98104

MAILING ADDRESS:
Harborview Medical Center, 325 9th Ave, Box #359928, Seattle, WA 98104

Privileged, confidential or patient identifiable information may be contained in this message. This information is meant only for the use of the intended recipients. If you are not the intended recipients. If you are not the intended recipient, or if the message has been addressed to you in error, do not read, disclose, reproduce, distribute, disseminate or otherwise use this transmission. Instead, please notify the sender by reply e-mail, and then destroy all copies of the message and any attachments.

<PastedGraphic-8.tif>
Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-1000
FAX: (301) 496-4409
E-mail: anthony.fauci@nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Siegel, Marc <Marc.Siegel@nyulangone.org>
Sent: Wednesday, January 22, 2020 7:03 AM
To: Fauci, Anthony (NIH/NIAID) [E] <anthony.fauci@nih.gov>
Subject: Re: Question

Just quoted you on Fox and Friends.
We want to know if you might be interested in coming to NYU to give Grand Rounds sometime over the next several weeks - on this coronavirus and vaccine candidate.
Grand Rounds are Wednesday mornings at 8 AM
It would be a great honor and pleasure to have you here.
We would of course cover all expenses and your fee.
Hope you will consider.
Marc

Sent from my iPhone

On Jan 22, 2020, at 5:52 AM, Fauci, Anthony (NIH/NIAID) [E] <anthony.fauci@nih.gov> wrote:

[EXTERNAL]
Marc:

You certainly can quote me.

Best regards,

Tony

From: Siegel, Marc <Marc.Siegel@nyulangone.org>
Sent: Tuesday, January 21, 2020 10:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b)(6)
Subject: Re: Question

thanks Tony!

hope I can quote you!

From: Fauci, Anthony (NIH/NIAID) [E] <(b)(6)
Sent: Tuesday, January 21, 2020 10:00:21 PM
To: Siegel, Marc
Subject: RE: Question

[EXTERNAL]

Marc:

Thanks for the note. We are already working on a vaccine for the 2019 n-CoV. We have the sequence of the virus and are employing an mRNA vaccine platform in collaboration with the Moderna Company. We hope to have the candidate in Phase 1 trials within 3 months. You might remember that we actually developed a DNA vaccine for SARS (another coronavirus pathogen) several years ago and brought it through Phase 1 trials showing safety and immunogenicity. We never developed it further since the SARS outbreak was completely stopped by good public health measures. Bottom line is that there is a good chance that over time, we will develop a vaccine for this virus.

Best regards,

Tony

-----Original Message-----
From: Siegel, Marc <Marc.Siegel@nyulangone.org>
Sent: Tuesday, January 21, 2020 4:41 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b)(6)
Subject: Question

Tony

Any chance of a vaccine for this coronavirus?
I believe they were testing one in dogs.

Marc

Sent from my iPhone
No down side in re-affirming statement

On Jan 28, 2020, at 1:22 PM, Collins, Francis (NIH/OD) [E] wrote:

Hi Tony,

See below. NIH signed the 2015 statement. Do you see any negatives in re-affirming this?

Francis
Dear All,

**Joint statement on sharing research data and findings relevant to the novel coronavirus (nCoV) outbreak**

I am writing to ask your organisation to recommit to a joint statement to rapid and open sharing of research data and findings relevant to the coronavirus (2019-nCoV) outbreak in China. The text of the joint statement follows below. Please do also share with others who may not be on this list.

This statement updates the 2016 [joint statement on data sharing in public health emergencies](https://www.wellcome.ac.uk), to which your organisation was a signatory.

In light of the urgent global health threat presented by this outbreak, we are asking signatories to reaffirm their commitment to these principles and pledge to also ensure research findings of relevance are shared rapidly with WHO. This statement reflects the public commitments already made by several leading journals over the last few days. It is aimed at researchers globally, and is necessary because of the unprecedented speed and number of research papers in response to the outbreak.

We plan to publish this statement before the end of the day on Thursday 30 January, so please let us know by 14:00 GMT on Thursday if you would like to sign.

Please reply to my colleague David Carr at Wellcome ([d.carr@wellcome.ac.uk](mailto:d.carr@wellcome.ac.uk)), who will also be happy to answer any questions you have.

With best wishes,

Jeremy Farrar

**PROPOSED JOINT STATEMENT**

Sharing research data and findings relevant to the novel coronavirus (nCoV) outbreak

The outbreak of the novel coronavirus in China (2019-nCoV) represents a significant and urgent threat to global health.

We call on researchers, journals and funders to ensure that research findings and data relevant to this outbreak are shared rapidly and openly to inform the public health response and help save lives.

We affirm our commitment to the principles set out in the 2016 [Statement on data sharing in public health emergencies](https://www.wellcome.ac.uk), and pledge to ensure that the World Health Organization has rapid access to emerging findings that could aid the global response.

Specifically, we commit to work together to ensure:

- all peer-reviewed research publications relevant to the outbreak are made immediately open access
• research findings relevant to the outbreak are shared immediately with the WHO upon journal submission, with author approval
• research findings are made available via preprint servers at or before journal submission, or via platforms that make papers openly accessible before peer review – with clear statements regarding the availability of underlying data
• interim and final research data relating to the outbreak are shared as rapidly and widely as possible, including with public health and research communities and the WHO
• journals are clear that data or preprints shared ahead of submission will not pre-empt its publication in these journals

We will apply the principles of this statement to similar outbreaks in the future where there is a significant public health benefit to ensuring data is shared widely and rapidly. We urge others to make the same commitments. If your organisation is committed to supporting these principles, please contact us (d.carr@wellcome.ac.uk) and we will add your organisation to the list of signatories.

SIGNATORIES TO THE STATEMENT ON EBOLA

• Academy of Finland
• Academy of Medical Sciences, UK
• Bernhard Nocht Institute for Tropical Medicine
• Bill and Melinda Gates Foundation
• Biotechnology and Biological Sciences Research Council (BBSRC)
• The British Medical Journal (BMJ)
• Bulletin of the World Health Organization
• Calouste Gulbenkian Foundation – Gulbenkian Science Institute
• Canadian Institutes of Health Research
• The Centers for Disease Control and Prevention (to include Morbidity and Mortality Weekly Report [MMWR])
• Chinese Academy of Sciences
• Chinese Centre for Disease Control and Prevention
• The Department of Biotechnology, Government of India
• The Department for International Development (DFID)
• Deutsche Forschungsgemeinschaft (DFG)
• eLife
• EcoHealth Alliance
• The Economic and Social Research Council (ESRC)
• EMBO Press
• F1000
• Fondation Mérieux
• Fundação Oswaldo Cruz (Fiocruz)
• The Global Health Network
• Global Virus Network
• GlaxoSmithKline (GSK)
• The Institut Pasteur
• Instituto Butantan, Brazil
• Instituto Nacional de Salud, Peru
• International Severe Respiratory and emerging Infection Consortium (ISARIC)
• International Society for Infectious Diseases
• Japan Agency for Medical Research and Development (AMED)
• The JAMA Network
• The Lancet
• Médecins du Monde/Doctors of the World (MdM/DoW)
• Médecins Sans Frontières/Doctors Without Borders (MSF)
• MicrOne Limited
• National Academy of Medicine
• National Institutes of Health, USA
• National Institute for Infectious Diseases Lazzaro Spallanzani (INMI), Italy
• National Science Foundation, USA
• The New England Journal of Medicine (NEJM)
• PLOS
• ProMED
• Research Ideas and Outcomes (RIO) Journal
• The Rockefeller University Press
• The Royal Society
• SAB Biotherapeutics
• Science Journals
• ScienceOpen
• South African Medical Research Council
• Springer Nature
• Thieme Publishers
• UK Medical Research Council
• Universidade Jean Piaget de Capo Verde
• USAID
• Wellcome Trust
• ZonMW – The Netherlands Organisation for Health Research and Development

Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.

The Wellcome Trust is a charity registered in England and Wales, no. 210183. Its sole trustee is The Wellcome Trust Limited, a company registered in England and Wales, no. 2711000 (whose registered office is at 215 Euston Road, London NW1 2BE, UK)
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 16:24:12 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD - Washington Post on camera interview re Wuhan
Attachments: Media Request: Wuhan coronavirus/WashPost VIDEO, RE: Media Request: Wuhan coronavirus/WashPost VIDEO

Reported: Amber Ferguson, video editor
Organization: Washington Post, video
Phone #s: 202-334-4194 (Desk) [ ] (cell) amber.ferguson@washpost.com
Subject: Coronavirus, how to control outbreaks, how they have been controlled in past
Deadline: Loose—early week of Feb. 3
Spokesperson: NIAID Director Dr. Anthony S. Fauci
Expected place of publication (print, online, broadcast): online video story on WashPost.com
Expected date of publication/airing: unknown
Expected prominence (e.g. front page, Sunday, evening/morning show, etc.):
Key messages/talking points:
Additional information:

Patty,
She wants to come with camera to ASF office later this week or early next to film a video story. Please see her message to me below.
Hello Anne,

My name is Amber Ferguson and I’m a video producer/editor at The Washington Post. We are working on a video about how infectious diseases spread and if containment practices work. We would like to interview Dr. Fauci on-camera about the coronavirus and get his thoughts on past infectious outbreaks. We would be able to come to NIH. Could we schedule this for this Wednesday or Thursday or anytime early next week? Please let me know if you have any questions and if we can set up an interview.

Thank you,
Amber
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 19:37:31 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD - Radio Free Asia Coronavirus Taped on Camera
Attachments: RE: Dr Fauci interview
Yes, we’re confirmed for 10:25AM ET tomorrow.
The on-site contact is: Bryan McCarthy who can be reached at [b] (6)
We are on floor 5 at 400 North Capitol NW
I’ll be in NYC, but can also be reached with any questions at [b] (6)

From: Ciniglio, Brianna <brianna.ciniglio@FOXNEWS.COM>
Sent: Thursday, January 23, 2020 9:50 AM
To: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>
Subject: Fox News Cavuto Saturday Request

Good morning,

I work on Neil Cavuto’s weekend show on Fox News. I am reaching out to see if Director Fauci would be available to join our show this Saturday at any point between 10AM-12PM ET to discuss the coronavirus. We will be live from NYC, but can arrange a remote interview. Please let me know if there’s any way we can make something work.

Thank you,

Brianna Ciniglio
Booker, “Cavuto LIVE”
Fox News Channel
Office: (212)-301-5051
Cell: [b] (6)
From: Fauci, Anthony (NIH/NIAID) [E]
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: CORONAVIRUS UPDATE TO IC DIRECTORS (8 am -8:15 am)
Marat Sadana
Shanghai Media Group

Topic: Wuhan pneumonia
Deadline: Wednesday 1/22 COB

Hi Patty,

This is a student reporter who is working for Shanghai Media Group’s video division, PearVideo. (See attached earlier email exchange—their info checks out, and the video will likely be broadcast here: https://www.pearvideo.com/) They’d like to set up a 20-minute Skype interview with Dr. Fauci, which will be taped for later broadcast. They’d like to do this ASAP (no solid deadline, but would need to do today or tomorrow). They sent the following questions:

1. Could you briefly introduce for us about what’s special about 2019-nCoronavirus?
2. any possible speculation about the source of infection 2019-nCoronavirus? (animals?)
3. How transmissible 2019-nCoronavirus could be? What are the possible routes of infection?
4. 2019-nCoronavirus is confirmed to possibly transmit from people to people. What does this mean? Any further possible serious effect?
5. It is said NIH has begun to develop vaccine. How soon we could have it?
6. Any suggestion for public? How can we protect ourselves from 2019-nCoronavirus so far?
Hope all is well.
We’ve worked together when I was at AJE and CGTN AMERICA. I moved to FBN in NYC.

I am reaching out to you to check the availability of Dr Fauci for an interview tomorrow 01/23 sometime between 10a-12pmET to talk about the coronavirus. This is a 5min LIVE hit for our show, Varney & CO. The name of the anchor is Stuart. We can book NIH TV studios.

Can he accommodate?  

Please let me know.

Joana

Joana Godinho | Fox Business Network
Coordinating Booker, Varney & Co.

1211 Avenue of the Americas  New York, NY 10036
E: joana.godinho@foxbusiness.com  O: 212-601-2941  C: (b) (6) (personal)
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 20:37:06 +0000
To: Fauci, Anthony (NIH/NIAID) [E]; Akinso, Woleola (NIH/OD) [E]; Akinso, Woleola (NIH/OD) [E]; Conrad, Patricia (NIH/NIAID) [E]
Cc: PRe-Tape with Brett Baer Corona | Taped on camera
Subject: RE: Bret Baier Request for Anthony Fauci, PRe-Tape with Brett Baer Corona (Taped on camera)

My name is Ashley Moir and I'm the booker for "Special Report w/ Bret Baier" at Fox News Channel in Washington, DC.

Bret was wondering if Dr. Fauci would be available to join us on the show in the 6pm hour this coming Monday, January 27 to discuss the latest with the Coronavirus.

Please get back to me at your earliest convenience. Thank you for considering!

Best,
Ashley

Ashley Koerber Moir
Booking Producer
Special Report w/ Bret Baier
Fox News Channel – DC Bureau

(6) (6) (cell)
E&C staff would like to have the full committee, Member-level briefing on Coronavirus on Thursday morning (Jan. 30) starting at 9:45am
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 23:13:44 +0000
To: Fauci, Anthony (NIH/NIAID) [E]; Awwad, David (NIH/NIAID) [C]
Subject: Yahoo online skype interview (Live hit 2:00 pm - 2:15 pm ET)
Attachments: FW: (Monday, 2-3 p.m.?) Yahoo Finance TV interview request -- Dr. Anthony Fauci
Subject: Wuhan coronavirus

Organization: Fox News Channel Fox Business Network

Specific Outlet Show: Bulls and Bears

Taped or live: Live at 5:12 p.m. Jan. 30

Deadline: Today Jan. 30

Reporter: David Asman (program host, doing interview)

Producer: Haley Gillman

Phone #(s) or e-mail: 646-468-1720 haley.gillman@foxnews.com

Agency spokesperson: NIAID Director Dr. Anthony S. Fauci

Expected place of publication: Fox News program Bulls and Bears

Expected date of publication/airing: Jan. 30 at 5:12 pm ET
Let us discuss whether we can do this during the coming week.

Dear Anthony, This is Wendy from Science Vs - we interviewed you last year about our episode on Pandemics, thank you so much. More than 500,000 people heard the episode.

With the new Wuhan coronavirus - we'd like to do a quick, follow up interview. What's happening? Where did this come from? (Snakes?) How worried should we be?

Is there any chance you're available early next week? We'd need around 30 minutes.

Thank you

Wendy

Sent from my iPhone

On Oct 8, 2019, at 1:17 PM, Fauci, Anthony (NIH/NIAID) [E] wrote:

Some flu vaccines (relatively small proportion) are grown in cells as opposed to eggs. This is somewhat more reliable but not really faster. A very small percentage are developed through recombinant DNA technology and this is faster. We are trying to convert much more to the recombinant vaccine platforms but we are not there yet.

On Oct 8, 2019, at 6:21 PM, Wendy Zukerman <wendyz@gimletmedia.com> wrote:

Thanks - regarding the question about growing vaccine in chicken eggs. Do we have alternate (non-chicken egg/ faster) technology available right now, but it hasn't been rolled out? Or, do we need to develop better vaccine making technology?

thank you so much.
On Tue, Oct 8, 2019 at 2:02 AM Fauci, Anthony (NIH/NIAID) [E] <(b) (6) wrote:
Rough estimate assuming a conservative 20% infection rate and a 2% mortality I would estimate 1.5 million deaths in the USA and ~35 million global.

On Oct 8, 2019, at 12:53 AM, Wendy Zukerman <wendyz@gimletmedia.com> wrote:
Thank you! And if we’ve been going back and forth on what our final “death toll” should be. We’re assuming highly contagious, with a 2% mortality rate, vaccine arrives around 6 months in, episode ends at 7 months. Do you think 2 million in the US would make sense? And worldwide, 33, 35 million or 40 million?

On Mon, Oct 7, 2019 at 4:04 PM Fauci, Anthony (NIH/NIAID) [E] <(b) (6) wrote:
Pandemics will occur and we cannot “prevent” them, but we can mitigate their impact and prevent worst case scenarios. There are several ways to do this. Three of the most important are: 1) improve global surveillance so that we can get a head start on response such as development of a vaccine. 2) improve vaccine platform technology and manufacturing capabilities to allow rapid development of vaccines. 3) stockpile readily deliverable interventions such as respirators, antivirals and antibiotics for bacterial complications.

On Oct 7, 2019, at 9:35 AM, Wendy Zukerman <wendyz@gimletmedia.com> wrote:
Hi Tony, We’re almost out of the woodwork with all the fact checking! Thank you for your time. Quick question. What are the top three things can we do now to help prevent a worst case scenario flu pandemic?

Best, Wendy

---
Wendy Zukerman
Host and Executive Producer
Science Vs podcast
wzukerman@spotify.com

---
Wendy Zukerman
Host and Executive Producer
Science Vs podcast
wzukerman@spotify.com

Wendy Zukerman
Host and Executive Producer
Science Vs podcast
wzukerman@spotify.com
Great! I am anxious to learn of your impression.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
E-mail:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

Tony,
I've been invited to China by the central govt. details to follow

On Jan 23, 2020, at 6:05 PM, Fauci, Anthony (NIH/NIAID) [E] wrote:

Thanks, lan.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
Tony,
See translation of Mandarin text regarding age and baseline medical status in the 17 Wuhan CoV fatalities.

Ian

As of 24:00 on January 22, our committee had received a total of 571 confirmed cases of pneumonia of new coronavirus infection in 25 provinces (autonomous regions, municipalities) in China, including 95 severe cases and 17 deaths (all from Hubei Province). A total of 393 suspected cases were reported in 13 provinces (autonomous regions and municipalities).

At 00:00 on the 22nd, 24 provinces (autonomous regions and municipalities) reported 131 new confirmed cases and 8 new deaths, including 5 males and 3 females. 13 provinces (autonomous regions and municipalities) reported 257 new suspected cases. A total of 25 provinces (autonomous regions and municipalities) reported the epidemic.

Confirmed cases reported overseas: 1 case in Hong Kong, China, 1 case in Macau, 1 case in Taiwan, China; 1 case in the United States, 1 case in Japan, 3 cases in Thailand, and 1 case in South Korea.

At present, 5897 close contacts have been traced, 969 people have been released from medical observation, and 4928 people are still receiving medical observation.

Introduction of 17 deaths
I am attaching 2 copies of the manuscript with my tracked changes showing and a clean copy.
Looks fine. Please see my comments in attached document.

Thanks,
Tony
The message is clear and appropriate. I support it.

From: GPMB Secretariat <gpmbsecretariat@who.int>
Sent: Tuesday, January 28, 2020 7:09 AM
To: As Sy Elhadj; Brundtland Gro Harlem; Dzau, Victor J.; Chris, Elias; Farrar Jeremy; Fauci Anthony; Fore Henrietta; Gao Fu; Gashumba Diane; Kaag Sigrid; Ilona Kickbusch; Suzuki Yasuhiro; Vega Morales Jeanette; VijayRaghavan Krishnaswamy; 'Skvortsova Veronika'; MAHJOUR, Jaoaad; MINHAS, Raman; Toomas Palu; Pate Muhamed; RYAN, Michael J.; SCHWARTLANDER, Bernhard F.; Alveberg, Benedikte Louise; Chiaki NOGUCHI; Esved Marja; Esved Marja; Gonggrijp Mette; Julie.HALL; Kanarek, Morgan; Marston Hilary; Omar Abdi; Amelie ROUUX; Goda Tore; GABEDEVA, Tsira; ROSS, Alex; Banks Lynn; Block, Bruce; Del Sol Dinia; Diao Fay; Gahungu Zacharie; Harikumar M K; Harikumar M K; Kabagire Christine; KITA Yosuke; 'Steve Smith'; MURIUKI, Hilda Wairimu; Muzenda Sindiso; Sarah Belmir; YU Bai; Kirsi Madi; 'Oleg Sonin'

Subject: TIME SENSITIVE Message from GPMB Co-Chairs: review of draft GPMB Statement on 2019-novel coronavirus

Importance: High

Dear Board members,

Thank you to all who participated in yesterday’s teleconference call regarding the novel 2019-Coronavirus outbreak.

We received excellent updates from WHO and from Professor Gao.
There was consensus for the GPMB to issue a statement supportive of countries’ (especially China) and WHO response efforts, and to call for urgent actions to further strengthen global preparedness and response to this outbreak.

Please find attached a draft GPMB Statement.

We ask that you please send us any feedback (preferably in track change mode) no later than 1700 Wednesday 29 January, Geneva time

Thank you very much.

Kinds regards,

Gro and As
Top NIH doctor wants China to invite US disease detectives to inspect Wuhan coronavirus data

From CNN Health’s Elizabeth Cohen

The United States’ top infectious disease doctor wants a team of disease detectives from the US Centers for Disease Control and Prevention to go to China and check on crucial questions about how the Wuhan coronavirus is spreading.

But there’s one problem: China first has to invite the CDC.

“Up to now, to my knowledge, we have not been invited,” said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the US National Institutes of Health.
A CDC spokesperson was not immediately available to comment on Sunday. NIH and CDC are separate divisions of the US Department of Health and Human Services.

On Sunday, Ma Xiaowei, China’s health minister, told reporters that the virus could spread before someone develops symptoms. If so, that means the virus will spread much more quickly than expected. Ma did not explain how Chinese authorities arrived at this conclusion.

“The implications for this are so important that in my mind it’s absolutely critical that we ourselves see the data, because what goes on over there has implications for what happens here,” Fauci said.

Fauci said that CDC disease detectives would need to see precisely how Chinese health authorities have gathered their data.

“To my knowledge, we have not seen the precise minute, granular data and how they collected it,” he said. “We need to get to the real bottom line of how they collected their data and see if it’s valid.”

“The Chinese have good people. I don’t want to impugn their capabilities,” Fauci added. “But when it’s something as important as this, our people who are trained epidemiologists need to go over their data and the best way to do that is go there and see how they’re collecting it.”

He added that to his knowledge, the Chinese did not tell US health authorities that the virus could spread before someone is symptomatic, a crucial aspect of any disease investigation. He said he learned about it after reading a CNN reporter’s email.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 02:02:08 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: Our NIAID supported SARS receptor binding domain vaccine (from China)

As per prior e-mail. See attachments.

From: Hotez, Peter Jay [b] (6)>
Sent: Monday, January 20, 2020 8:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] [b] (6) Stemmy, Erik (NIH/NIAID) [E] [b] (6)
Cc: Bottazzi, Maria Elena [b] (6) Hotez, Peter Jay [b] (9)>
Subject: Re: Our NIAID supported SARS receptor binding domain vaccine (from China)

Dear Tony and Erik, I hope it's OK I'm emailing you directly, but given the emerging situation I thought it would be wise.

Warm regards, Peter

Peter Hotez, MD, PhD, FASTMH, FAAP
Dean, National School of Tropical Medicine
Professor, Departments of Pediatrics, Molecular Virology & Microbiology
Co-Head, Section of Pediatric Tropical Medicine
Health Policy Scholar

NIH-002555
Baylor College of Medicine

Texas Children’s Hospital Endowed Chair of Tropical Pediatrics
Co-Director, Texas Children’s Hospital Center for Vaccine Development

University Professor

Department of Biology, Baylor University

Faculty Fellow, Hagler Institute for Advanced Study
Senior Fellow, Scowcroft Institute of International Affairs
Texas A&M University

Baker Institute Fellow in Disease & Poverty and Adjunct Professor of Bioengineering, Rice University

Adjunct Professor, University of Texas, School of Public Health

Founding Editor-in-Chief, PLoS Neglected Tropical Diseases

E-mail: 
Twitter: 
Skype: 
Website: 

Amazon Author Center: https://www.amazon.com/Peter-J.-Hotez/e/B001HPIC48
Like us on Facebook https://www.facebook.com/BCMNationalSchoolOfTropicalMedicine/

Executive Assistant: 

Phone: 

NIH-002556
From: Hotez, Peter Jay
Sent: Monday, January 20, 2020 7:17 PM
To: Anthony (NIH/NIAID) [E] Fauci <(b) (6)>
Cc: Bottazzi, Maria Elena; Hotez, Peter Jay
Subject: Our NIAID supported SARS receptor binding domain vaccine (from China)

Dear Tony and Erik, I hope it's OK I'm emailing you directly, but given the emerging situation I thought it would be wise.

Warm regards, Peter

Peter Hotez, MD, PhD, FASTMH, FAAP
Dean, National School of Tropical Medicine
Professor, Departments of Pediatrics, Molecular Virology & Microbiology
Co-Head, Section of Pediatric Tropical Medicine
Health Policy Scholar
Baylor College of Medicine

Texas Children’s Hospital Endowed Chair of Tropical Pediatrics
Co-Director, Texas Children’s Hospital Center for Vaccine Development

University Professor
Department of Biology, Baylor University

Faculty Fellow, Hagler Institute for Advanced Study
Senior Fellow, Scowcroft Institute of International Affairs
Texas A&M University

Baker Institute Fellow in Disease & Poverty and Adjunct Professor of Bioengineering, Rice University
Adjunct Professor, University of Texas, School of Public Health

Founding Editor-in-Chief, PLoS Neglected Tropical Diseases

E-mail: (b) (6)
Twitter: (b) (6)
Skype: (b) (6)
Website: (b) (6)

Amazon Author Center: https://www.amazon.com/Peter-J.-Hotez/e/B001HPIC48
Like us on Facebook https://www.facebook.com/BCMNationalSchoolOfTropicalMedicine/

Executive Assistant: (b) (6)
Please respond for me. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

As I mentioned, I would just say a number of diagnostic developers are exploring use in their platform. Since none have publicly announced their plans, we would not want to get ahead of their planning.

See question below.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b)(6)
From: Madeleine Johnson <madeleine.johnson@genomeweb.com>
Sent: Thursday, January 23, 2020 12:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] <removed>
Subject: question from a reporter about Dx mention in JAMA article

Dear Dr. Fauci, My name is Madeleine Johnson and I am a reporter at GenomeWeb.com and 360Dx.com covering diagnostic technologies.

I'm writing a short feature story on companies and agencies developing diagnostic tests for 2019-nCoV. I noted in your JAMA Viewpoint article today that you and your co-authors refer to this as well.*

So far, I am aware of RT-qPCR tests developed by CDC, a lab in Germany, Co-Diagnostics, and BGI, and the possibility of rapid sequencing-based testing being developed by Oxford Nanopore. Are you aware of any others that you can disclose, on or off the record?

Also, I imagine that a rapid, near-patient diagnostic test would be the ideal in outbreak control. Are you aware of any pan-coronavirus tests that could be adapted for screening, or any sign that specific point of care molecular diagnostic platform developers are working on rapid MDx for use in airports or ERs, etc?

I am sure you are extremely busy, but even a few brief comments via email would be amazing! I am hoping to run a story later this afternoon (~3PM Eastern) but can also add it once it is published online, if needed.

Thanks so much! Madeleine

*"For example, platform diagnostic modalities are being rapidly adapted to include 2019-nCoV, allowing early recognition and isolation of cases."
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 11:37:15 +0000
To: Marston, Hilary (NIH/NIAID) [E]

Thanks!

From: Marston, Hilary (NIH/NIAID) [E]
Sent: Tuesday, January 28, 2020 6:56 PM
To: Fauci, Anthony (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Steven T. Smith; Handley, Gray (NIH/NIAID) [E]


Consolidated comments from me and from Steve Smith.
Subject: TIME SENSITIVE Message from GPMB Co-Chairs: review of draft GPMB Statement on 2019-novel coronavirus

Importance: High

Dear Board members,

Thank you to all who participated in yesterday's teleconference call regarding the novel 2019-Coronavirus outbreak.

We received excellent updates from WHO and from Professor Gao.

There was consensus for the GPMB to issue a statement supportive of countries' (especially China) and WHO response efforts, and to call for urgent actions to further strengthen global preparedness and response to this outbreak.

Please find attached a draft GPMB Statement.

We ask that you please send us any feedback (preferably in track change mode) no later than 1700 Wednesday 29 January, Geneva time.

Thank you very much.

Kinds regards,

Gro and As
Please respond to this person. Thanks.

From: Beilier, Jeremy R. (b) (6)
Sent: Wednesday, January 29, 2020 12:17 AM
To: Fauci, Anthony (NIH/NIAID) (b) (6)
Subject: Wuhan coronavirus treatment candidate

Dear Dr. Fauci:

I am a physician-scientist at Columbia University and study human acute respiratory distress syndrome (ARDS). I am not a virologist. However, I read with interest your JAMA viewpoint on Wuhan 2019 nCoV and noted a potential prophylaxis/treatment that was not mentioned but that may be of interest.

From my ARDS research, I am familiar with a recent GSK study of recombinant human angiotensin-converting enzyme-2 (rhACE2) for ARDS (NCT01597635), for which it showed some promise. Regardless, it may be an effective treatment for Wuhan coronavirus.

As you noted, ACE2 is a main binding site for SARS. In lab models, soluble ACE2 appears effective at inhibiting propagation of SARS. Early published data for Wuhan CoV suggest it also may bind to ACE2 (Xu et al. Science China Life Sciences 2020:53). If Wuhan CoV indeed binds to ACE2, then rhACE2 might be effective at attenuating illness severity or blocking transmission. Given the established safety profile of rhACE2 from the prior GSK human trials, it seems to me an excellent candidate therapy for prophylaxis (not ideal in the studied iv formulation) or treatment if the Wuhan nCoV outbreak continues to grow.

I imagine you and others have already thought of this. Since I do not recall seeing it in the JAMA paper, I thought it worth sharing only because it is a treatment potentially immediately ready for testing.

Thank you for considering,
Jeremy
Cell: (b) (6)

Jeremy R. Beilier, MD, MPH
Assistant Professor
Director of Clinical Research
Center for Acute Respiratory Failure
They will send a crew.

From: Monday, January 20, 2020 11:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] <fauci@nih.gov>
Cc: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>
Subject: Interview Invitation on coronavirus outbreak in China

Dear Dr. Fauci,

I'm Youyou Wang from Hong Kong Phoenix TV, Washington DC bureau. I would like to invite you for a TV interview on coronavirus outbreak in China.

The situation in China is very fluid. We would really appreciate if you could share some insights on coronavirus. Your expertise in this area would be extremely valuable for our audience at this critical moment.

Please kindly let us know if you could accept our invitation, and your earliest availability. We could come to NIH earlier to set up for the interview.

Looking forward to hearing back from you!

Best regards,

王又又 | Youyou WANG

Correspondent
Washington D.C. Bureau | Phoenix Satellite Television

Phone: +(1)(202)715-0352 | Fax: +(1)(202)715-1374
Mobile:  | E-mail: wangyouyou@phoenixtv.com
101 Constitution Ave NW | Suite 920 EAST | Washington DC 20001

NIH-002579
Patty:

Please set something up for me to have a conversation with Janet.

Thanks,

Tony

From: Janet Tobias <janet@ikanamedia.com>
Sent: Sunday, January 26, 2020 9:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b)(6) Conrad, Patricia (NIH/NIAID) [E] <(b)(6)
Cc: Rancourt, Anne (NIH/NIAID) [E] (b)(6)
Subject: Coronavirus and interview for the film

Dear Tony and Patty: I know you must be extremely busy. I talked to Anne last week and told her I was going to write to you both to put in place an interview in

Janet
Please respond to this person.

From: Austin Avino
Sent: Wednesday, January 29, 2020 12:20 AM
To: Fauci, Anthony (NIH/NIAID) <(b)(6)>
Subject: Possible Coronavirus cure

My name is austin avino. I am not a dr. Or a med student. I have been doing research on coronavirus and know it can be in both animals anc humans. Through furthere research i found out that there is one animal in particular that has almost an immunity to all deseases some professionals have discovered. The shark. They have squalimine that years ago was tested against cancer but was not sucessful. Coronavirus is a respritory desease and i have been thinking what is the best way to get medicine in the lungs. There is a squalamine inhalant that has been tested on rats to treat certain strands of pneumonia. After several days of being applied 2 doses of the inhalant daily the percentage of the pneumonia bacteria dropped. I do not know if this would work or not but it would be worth finding a cure for a disease without a cure at the moment. Lab testing a coronavirus strand to see if squalamine can fight back against it would be worth a shot and could save thousands of people. If you have any questions feel free to email me.
I have not heard anything definite about the dynamics of the infection of the 14 healthcare workers.

-----Original Message-----
From: Cohen, Elizabeth <Elizabeth.Cohen@turner.com>
Sent: Tuesday, January 21, 2020 6:01 AM
To: Fauci, Anthony (NIH/NIAID) [E] <boby@boby.com> (boby)
Subject: Re: Vaccine for new Chinese coronavirus in the works - CNN

Tony —
Many thanks. Please let me know if there’s anything else in particular you think we ought to be reporting today. We’re trying to learn more about these 14 healthcare workers. Have you heard whether it was just one patient who infected all of them?
Cheers,
Elizabeth

> On Jan 21, 2020, at 12:51 PM, Fauci, Anthony (NIH/NIAID) [E] <boby@boby.com> (boby) wrote:
> Elizabeth:
> Nice piece!
> Best,
> Tony
>
> ----Original Message-----
> From: Cohen, Elizabeth <Elizabeth.Cohen@turner.com>
> Sent: Tuesday, January 21, 2020 12:21 AM
> To: Fauci, Anthony (NIH/NIAID) [E] <boby@boby.com> (boby)
> Subject: Vaccine for new Chinese coronavirus in the works - CNN
>
> Tony - thank you for your help with this. Looking forward to speaking today to see if we’ve learned more about this virus.
>
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 02:28:36 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: From Italy

Please set this up IF it is possible.

From: Michele Bocci <m.bocci@repubblica.it>
Sent: Saturday, January 25, 2020 8:21 AM
To: Fauci, Anthony [NIH/NIAID] [E] <(b) (6)
Subject: From Italy

Hello, I’m a journalist from the Italian national newspaper La Repubblica and I’d like to have an interview with you about the new coronavirus. Just some question about it’s nature and it’s dangerousness. Is it possible?

Thank you,
Michele Bocci
Thanks, Wayne.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b)(6)
FAX: (301) 496-4409
E-mail: [redacted] (b)(6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

From: Wayne Holman
Sent: Wednesday, January 29, 2020 9:16 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b)(6)
Subject: 2019-nCoV: Could anti-IL6 be helpful if cytokine storm is driving the pathology in the sickest patients?

Hi Tony,
I share Wendy’s view of the amazing work you and your team. Many thanks from a grateful nation.

The literature suggests that those who are asymptomatic have lower levels of cytokines and those who are highly symptomatic have something of a cytokine storm. In the CART field uses anti-IL6 monoclonals to treat the CRS. I wonder if anti-IL6 would work for these patients. The literature describes steroid use but perhaps IL-6 is more targeted, less immunosuppressive and more effective. I see literature describing IL-6 as key in SARS but not anti-IL6 use. The Lancet paper showed some modest change in the IL-6 levels in the 2019-nCoV patients relative to other cytokines however it could be a central mediator none-the-less. I know there is no easy answer.

Best Wishes,
Decoding the enigma of antiviral crisis: Does one target molecule regulate all?


Author information

Abstract

Disease fatality associated with Ebola, SARS-CoV and dengue infections in humans is attributed to a cytokine storm that is triggered by excessive pro-inflammatory responses. Interleukin (IL)-6 acts as a mediator between pro- and anti-inflammatory reactivity by initiating trans- and classical-signaling, respectively. Hence, IL-6 is assumed to provide a target for a broad range of antiviral agents. Available immunosuppressive antivirals are directed to control an often exaggerated pro-inflammatory response that gives rise to complex clinical conditions such as lymphocytopenia. It is known that IL-6, via its soluble receptor (sIL-6R), initiates a pro-inflammatory response while an anti-inflammatory response is triggered by the membrane-bound IL-6 receptor (IL-6R). Future antivirals should thus aim to target the mechanism that regulates switching between IL-6 trans- and classical-signaling. In this review, we propose that the tumour necrosis factor-α converting enzyme ADAM-17 could be the master molecule involved in regulating IL-6 class switching and through this in controlling pro- and anti-inflammatory responses to viral antigenic stimuli. Therefore, ADAM-17 should be considered as a potential target molecule for novel antiviral drug discovery that would regulate host reactivity to infection and thereby limit or prevent fatal outcomes.

Copyright © 2018 Elsevier Ltd. All rights reserved.

KEYWORDS:
ADAM-17; Antiviral; Cytokine storm; Dengue; Ebola; IL-6; Pro-inflammatory response; SARS-CoV; Virus
DISCLAIMER: This e-mail message and any attachments are intended solely for the use of the individual or entity to which it is addressed and may contain information that is confidential or legally privileged. If you are not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message or its attachments is strictly prohibited. If you have received this message in error, please notify the sender immediately and permanently delete this message and any attachments.
FYI

-----Original Message-----
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thursday, January 23, 2020 10:00 PM
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: coronavirus vaccine

Please take a look at this and respond to this person one way or another.

-----Original Message-----
From: J. Robert Coleman
Sent: Thursday, January 23, 2020 9:53 PM
To: Fauci, Anthony (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E] Cassetti, Cristina (NIH/NIAID) [E]
Subject: Re: coronavirus vaccine

Dear Dr. Fauci

Thank you for responding to Dr. Norton, I am sure you are being pulled in many different directions.

Thank you for your time and I look forward to hearing from NIAID. Best Regards, Robert Coleman

On Thu, Jan 23, 2020 at 7:08 PM wrote:
>
> Thank you so much! We need all the smartest minds (like yours) we can focus on this issue, I suspect with trepidation.
> >
> > I am fine but working too hard. I know you know that syndrome too!
> >
> > I trust all is well with you too.
> >
All my best.

Larry

From: Fauci, Anthony (NIH/NIAID) [E]  
Sent: Thursday, January 23, 2020 6:04 PM
To: Norton, Larry/President's Office  
Cc: Conrad, Patricia (NIH/NIAID) [E]  
Cassetti, Cristina (NIH/NIAID) [E]  
Subject: [EXTERNAL] RE: coronavirus vaccine

Larry:

Thanks for the note. Have them send me some material and I will forward it to the appropriate people here at NIAID. I hope that all is well with you.

Best regards,

Tony

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases Building 31,  
Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Please note that this e-mail and any files transmitted from Memorial Sloan Kettering Cancer Center may be privileged, confidential, and protected from disclosure under applicable law. If the reader of this message is not the intended recipient, or an employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any reading, dissemination, distribution, copying, or other use of this communication or any of its attachments is strictly prohibited. If you have received this communication in error, please notify the sender immediately by replying to this
message and deleting this message, any attachments, and all copies and backups from your computer.

J. Robert Coleman, PhD, MBA
Chief Executive Officer
Co-founder, Codagenix, Inc.
3 Bioscience Park Drive
Farmingdale, NY 11735-0176
Phone: (b) (6)

This e-mail (and any attachment) is intended solely for the use of the individual or entity to which it is addressed, and may contain proprietary, confidential or privileged information of Codagenix, Inc. and/or its subsidiaries. If you are not the intended recipient of this e-mail, or responsible for delivering this e-mail to the intended recipient, you are hereby notified that any dissemination, distribution, copying or other action taken with respect to this e-mail is strictly prohibited. If you have received this e-mail in error, please notify the sender immediately and permanently delete the original and any copy.
Dear Dame Sackler:

Thank you for your note. As you have probably already heard, the Chinese authorities have closed down the wet markets that sell exotic animals for consumption and are encouraging the population to avoid such consumption.

Best regards,

Tony

_________________________________________________________
From: (b)(6)
Sent: Friday, January 24, 2020 2:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b)(6)>
Subject: from Dame Jillian Sackler

Dear Dr. Fauci,

We met when you delivered the inaugural opening of The DJS Distinguished Lecture on Global Health Issues at the Foreign Policy Association. Thank you again. Of course the Sackler name has been completely destroyed - due to fake news: I have no opioid money, my husband Arthur had nothing to do with this scandal or any other nefarious behavior, he was a magnificent man.

Anyway, I have been involved with China for years, and have wondered why pathogens such as the Wuhan Coronavirus all seem to begin in China, considering India and other countries maintain unhygienic practices. I just read that Chinese health officials believe it originated at a market selling exotic live animals for food. such as crocodiles, rats, peacocks (more than 100 kinds of wildlife), they think the culprits may be snakes or bats. Perhaps your or another US health leader can pressure China to ban the merchandising and eating of wild animals.

Kind regards and happy Chinese Lunar New Year.

Dame Jillian Sackler
Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
Fax: (301) 496-4409
E-mail:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hank Safferstein <(b)(6)>
Sent: Wednesday, January 29, 2020 9:29 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b)(6)>
Subject: Assistance/Guidance

Dear Dr. Fauci,

I hope this email finds you well.

I was hoping to schedule a call with the appropriate person at NIAID to discuss in further detail.

Appreciate your help and thank you

Hank

--
Hank Safferstein, Ph.D., J.D., M.B.A.
CEO
Generian
Executive in Residence
Pittsburgh Life Sciences Greenhouse
2425 Sidney Street
Pittsburgh, PA 15203

Direct
Mobile
412-770-1276 Fax
Email

www.plsq.com
Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.
Imran:

Unfortunately, I am too swamped to do this right now. Sorry.

Best,
Tony

From: Ali, Imran X. -ND <imran.X.Ali.-ND@abc.com>
Sent: Friday, January 24, 2020 11:12 AM
To: Fauci, Anthony (NIH/NIAID) [E] <fauci.anthony.niaid@nih.gov>
Subject: Coronavirus..... Holy Cross Grad....

Greetings Dr. Fauci,

I hope you remember me. This is Imran Ali the Holy Cross Graduate who has been inspired by your work throughout the years. We met on several occasions and you were interviewed for my podcast. We have been in touch ever since you gave me your autographed photo way back in 1999.

I know that you are extremely busy right now doing what you do best informing the public and our lawmakers in the Senate today. As you can see I am a contributor to ABC News as a freelancer. I was wondering if you could reply briefly to the following questions that I could include in an article that I can send to my editor for consideration next week:

1. SO FAR WE HAVE 63 PATIENTS UNDER INVESTIGATION FROM 22 STATES WITH 2 TESTING POSITIVE AS OF FRIDAY JAN 24TH, 11 ARE NEGATIVE, HOW WORRIED SHOULD THE AMERICAN PUBLIC BE?

2. CORONAVIRUS HAS BEEN AROUND FOR MANY YEARS BUT WHAT MAKES THIS STRAIN DIFFERENT?
3. DURING THE EBOLA OUTBREAK WE ONLY HAD ABOUT 700 PEOPLE ARRIVING TO THE US EVERY DAY BUT NOW WE HAVE ALMOST 10,000 PEOPLE COMING FROM CHINA EVERY DAY.... IS THERE ANY USE IN CURTAILING FLIGHTS?

4. JUST LAST YEAR USAID HAS CUT FUNDING TO THE "PREDICT" PROGRAM THAT WAS INSPIRED BY THE 2005 H5N1 BIRD FLU SCARE, WOULD THIS PROGRAM BE HELPFUL IN BETTER UNDERSTANDING THE CORONA VIRUS?

5. FINALLY, IN A RECENT ARTICLE IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION IT WAS MENTIONED THAT BACK WHEN THE SARS VIRUS OUTBREAK A DNA VACCINE TOOK ABOUT 20 MONTHS TO DEVELOP BUT SINCE THEN WE HAVE mRNA VACCINE TECHNOLOGY, HOW QUICKLY COULD WE POTENTIALLY SEE A VACCINE FOR THIS CORONAVIRUS STRAIN?

Thank you very Dr. Fauci for your time if you are able to answer these questions.... I totally understand if you are busy and need to defer this as this is an article that I am volunteering not necessarily assigned at the moment

Sincerely,

Imran
Imran Ali MD MS MPH
Physician Fellow ABC News Medical Unit
Office 212-456-2632
Cell (b) (6)
Email Imran.X.Ali.-ND@abc.com
Personal Email: (b) (6)
Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [Redacted] 6
FAX: (301) 496-4409
E-mail: [Redacted] 6

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: RYAN, Michael J. [Redacted] 6
Sent: Wednesday, January 29, 2020 10:45 AM
To: Redfield, Robert R. (CDC/OD) [Redacted] 6
    David Heymann [Redacted] 6; Fauci, Anthony [Redacted] 6
    [Redacted] 6
    ; Cox, Paul Michael [Redacted] 6
    SHOC [Redacted] 6; Grein, Thomas [Redacted] 6
Cc: GHEBREYESUS, Tedros Adhanom [Redacted] 6; Schwartlander, Bernhard F. [Redacted] 6
    ; Minhas, Raman [Redacted] 6
Subject: Informal coronavirus teleconference, 29 January, 19.00 CET

Dear colleagues,

Dr Tedros would like to take the opportunity to informally discuss with you the ongoing 2019 novel coronavirus.

We are planning to host a teleconference today at 19.00 CET and will provide a dial-in number with a passcode.

If you face any difficulties with the dial-in number, please provide us with a contact number and we will attempt to dial you in.
Best,

Mike
Done!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
FAX: (301) 496-4409
E-mail:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Sent from my iPhone

Begin forwarded message:

From: Eileen O'Reilly <eileen@axios.com>
Date: January 20, 2020 at 8:17:07 PM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" <(b)(6)
Subject: Speak with Dr. Fauci on the coronavirus?

Hi Patricia:

Hope you had a nice holiday weekend.

Would Dr. Fauci have 10 minutes on Tuesday to speak about what we now know about the coronavirus linked to Wuhan?
Thanks,

Eileen O'Reilly, Axios

(0) (0)
eileen@axios.com
Sorry. Pressed “send” too soon. Let us discuss this next time we get together.

Best,

Tony

Bob:

Thanks for the note.

Hi Tony,

I want you to know GVN is very active internationally in the new coronavirus problem via its respiratory Watch Group.

Please let me know if you wish to discuss further.

Thanks and with my very best wishes,

Bob
Please set up a call with this person. It can wait until next week.

Dr. Fauci,
I’m a writer with Wired, and I’m interested in writing about the Wuhan coronavirus and particularly about the issue of super spreaders and the potential they pose to greatly increase transmission. (I know that both SARS and MERS had important incidents of super spreading.) I would love to get your perspective on this issue. A key question is how to detect super spreaders—yet it seems like that is still not well-understood. I was also intrigued with a couple of points raised in your JAMA article—particularly, why are most coronaviruses so benign that we call them “the common cold” but then in recent years we are having outbreaks of much more serious disease? And how quickly could a vaccine be produced—and how effective would it likely be?

Would you be available to talk in the next few days? (This afternoon would be awesome, if that’s possible. Or perhaps tomorrow late morning (10:30 or 11-ish?) or midday? Or please let me know if a different time would work.)


Thanks so much for your help!
-Michele

Michele Cohen Marill
Journalist/Writer
(404) 636-6021 (office)
(6)(6) (cell)
www.michelemarill.com
Can you listen in on this? It overlaps with an AMA call.

From: GPMB Secretariat <gpmbsecretariat@who.int>
Sent: Friday, January 24, 2020 9:39 AM
To: As Sy Elhadj; Brundtland Gro Harlem; Dzau Victor; Chris Elias; Farrar Jeremy; Fauci, Anthony [NIH/NIAID] [E]; Fore Henrietta; Gao Fu; Gashumba Diane; Kaag Sigrid; Ilona Kickbusch; Skvortsova Veronika; Suzuki Yasuhiro; Vega Morales Jeanette; VijayRaghavan Krishnaswamy; MAHJOUR, Jaouad; MINHAS, Raman; Toomas Palu; Pate Muhamed; RYAN, Michael J.; SCHWARTLANDER, Bernhard; Alex Harris; Alveberg, Benedikte Louise; Chiaki NOGUCHI; Esveld Marja; Gagfrijk Mette; Julie.HALL; Kanarek Morgan; Marston, Hilary [NIH/NIAID] [E]; Omar Abdi; Amelie RIOUX; Tore Godal; GABEDAVA, Tsira; ROSS, Alex; Banks Lynn; Block Bruce; Conrad Jane; Conrad, Patricia [NIH/NIAID] [E]; Del Sol Dinia; Diao Fay; Elena Kirshanova; Diahngu Zacharide; Harikumar M K; Harikumar M K; KITANO, Yosuke; Kabagire Christine; Miller de Vega Teresa; MURUKI, Hilda Wairimu; Muzenda Sindiso; Sarah Beomir; YU Bai
Cc: MAI

Subject: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY

Importance: High

Dear Board members,

As many of you, we are concerned about the Novel 2019-Coronavirus outbreak. We believe the Board has a role to play in supporting the response and encouraging countries to step up their preparedness activities, as well as to support WHO in their efforts.
As co-chairs of the GPMB we therefore suggest to hold a teleconference of the Board to discuss the outbreak.

An outcome of the call could be a GPMB statement supporting the response and highlighting crucial preparedness activities that should be undertaken, or other suggestions to be discussed.

We would suggest to hold the teleconference call on **Monday 27 January at 1400-1500 Geneva time**. This is the only time next week the Co-Chairs are available.

Attached is information for a telephone bridge for the call. We would appreciate it if you could please confirm your participation.

We will share with you shortly a more detailed agenda.

We look forward to hearing from you on this and thank you for your continued engagement.

Kinds regards,

Gro and As
Indeed, it happened 15 minutes after I sent you the e-mail. Embargoed until 3:00 PM ET

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

Thanks. Larry just gave me a heads up that your last sentence may have come true in WA.

Sent from my iPhone

On Jan 21, 2020, at 5:13 PM, Fauci, Anthony (NIH/NIAID) [E] wrote:

Francsi:

Thanks for the note. There is definite person-to-person transmission. 15 health care workers were infected in a Wuhan Hospital. We do not know about the degree of “sustained” person-to-person transmission. There have been 298 cases reported as of this AM with 6 deaths. The number is likely larger and is growing by the hour. We have already started working on a vaccine for the 2019 n-CoV. We are partnering with the Moderna Company using their mRNA vaccine
platform. We should be in Phase 1 trials (unless there are unforeseen issues) within 3 months. We are also pursuing any cross-reactivity of mAbs that we developed for SARS to see if they could be used as therapeutics for n-CoV. Other drugs such as remdesivir and ritonavir have been tried with MERS and may be useful. We would however, need the isolates (we just have sequence) to test these. We are already screening entries from China at JFK, LAX and SFO. I would not be surprised if just like SARS and MERS we ultimately see an imported case in the USA.

Hope that this is helpful.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
Fax: (301) 496-4409
E-mail: anthony.fauci@nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] <unnamed>(b)(6)
Sent: Tuesday, January 21, 2020 10:59 AM
To: Fauci, Anthony (NIH/NIAID) [E] <unnamed>(b)(6)
Subject: update on coronavirus?

HI Tony,

I will be in a Davos session on Thursday where response to the coronavirus outbreak will be a topic. Paul Stoffels will be there, as will Tedros.

What's now the best information about person-to-person transmission and mortality risk? Can you give me a quick precis of what the US is doing about risks of the illness coming to our shores? What do we know about possible therapies? And what is the plan to utilize the fastest possible platform to work on a vaccine?

Thanks, and sorry to hit you with this!
Francis
Please have me call him tomorrow.

From: John Lauerman (BLOOMBERG/ NEWSROOM;) <jlauerman@bloomberg.net>
Sent: Thursday, January 23, 2020 12:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] <fauci@nih.gov>
Subject: Interview on coronavirus

Hi Dr. Fauci: How are you? I have a few more questions that I think you could really help with. WHO has been saying this is a much quicker, more thorough and more transparent reaction than with SARS. We're trying to put together some early information about when the coronavirus first came to light, what the responses were, and what kinds of action were taken. Would you have some time to talk about this today or tomorrow? I'd just want to get some details about what you heard and when; I'm sure you've been on the case for a while. Thanks and regards, JL

John Lauerman, Bloomberg News
3 Queen Victoria Street, London, UK
tel. +44 (0) 2035 251028 cell 447 6062
http://www.bloomberg.com
http://www.bloomberg.com/prognosis
From: Tao Sun (b) (6)
Sent: Friday, January 24, 2020 2:45 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)
Subject: Dear Prof. Anthony Fauci, here is a request from MIT Technology Review (Chinese)

Dear Prof. Anthony Fauci,

I am Tao Sun, a reporter from Beijing. I am currently writing reports for the MIT Technology Review (Chinese).

JAMA published your article Coronavirus Infections—More Than Just the Common Cold, and Xinhua News Agency reported this article. Here are some questions I would like to ask you.

1. Some people think that it is not necessary to develop a new vaccine against SARS or coronavirus in Wuhan. The reason is that, firstly, there is no commercial interest to pharmaceutical manufacturers, and secondly, such outbreaks may not return after the extinction. What do you think of these views?

2. For the Wuhan virus vaccine being developed, the epidemic is likely to be eliminated after three months, so is it still necessary to develop a vaccine?

3. You can talk about SARS. How much does a vaccine against SARS actually play?

Looking forward to your reply.

--

TAO SUN

DEEPTECH MIT Technology Review

suntao@mittrchina.com

7th FL, Tower AB Office Park, 10 Jintong West Road, Chaoyang District, Beijing

http://www.mittrchina.com

NIH-002611
Looks fine. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
E-mail: anthony fauci@nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

Dr. Fauci —

I have drafted responses to Radio Free Asia for your review. Please let me know if you have edits. I will share the final version with the reporter on your behalf and I will note the responses are attributed to you.

Can we make medicine and vaccine against that virus? And if so, how long do you think is it going to take?

NIAID, part of the U.S. biomedical research agency NIH, has mobilized a research response to 2019-nCoV that builds on experience with SARS-CoV, MERS-CoV and other emerging pathogens. Scientists are continuing basic research to characterize the novel virus and understand how it causes disease, as well as developing diagnostics, vaccines and treatments.
We have begun early stage development of an mRNA (messenger RNA) vaccine for 2019-nCoV. mRNA vaccines direct the body’s cells to express a protein to elicit a broad immune response including high levels of neutralizing antibodies. The expressed protein is designed based on knowledge of the virus structure, but the platform does not contain live or inactivated virus. The mRNA platform can be quickly adapted and manufactured efficiently. NIAID and its industry partner Moderna anticipate the 2019-nCoV vaccine will be ready for the first stage of clinical testing in the coming months.

**Do you think it will be even more lethal if that virus spread in a country with poor health environment such as North Korea?**

At this stage it is difficult to predict how the virus will spread and cause disease in different regions. Experts around the globe are working to understand key epidemiological transmission features of 2019-nCoV and to characterize the severity and spectrum of disease. Certainly, a robust public health system that can effectively diagnose, isolate and care for patients and trace contacts is critical to controlling an emerging infectious disease.

Thanks,
Jen

Jennifer Routh
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892

Direct: (b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

Please have Jen prepare a response for me.

Albert Hong
Sent: Friday, January 24, 2020 10:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b)(6)
Subject: Media Inquiry
I'm Albert Hong, a reporter of the Radio Free Asia in Washington DC. I'm writing about a new virus, called 2019 novel coronavirus (2019-nCoV). I want to ask you:

1) Can we make medicine and vaccine against that virus?
2) And if so, how long do you think it will take?
3) Do you think it will be even more lethal if that virus spreads in a country with poor health environment such as North Korea?

Thank you and I'll be looking forward your comment.

Best,
Albert

----------------------------------------

Albert Hong
Broadcaster
Radio Free Asia- Korean Service
2025 M Street, NW., Washington DC 20036
Office (202) 266-4091

CONFIDENTIAL COMMUNICATION
This e-mail message is intended only for the use of the addressee and may contain information that is privileged and confidential. Any unauthorized dissemination, distribution, or copying is strictly prohibited.
If you receive this transmission in error, please contact network@rfa.org.
Visit us at www.rfa.org
I called and left voice mail

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4000
E-mail: anthony.fauci@mail.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alice Park <alice.park@time.com>
Sent: Tuesday, January 21, 2020 2:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] <anthony.fauci@mail.nih.gov>
Subject: Time request

Hi Dr. Fauci -- hope all is well, and happy new year!

I'm writing, as you can imagine, about the emerging coronavirus cases, w/the first reported case in the US (brought from Wuhan). I wanted to speak to you more generally about coronaviruses, what we know and how it typically transmits, what we've learned since SARS and MERS, and what if any specific challenges these viruses pose in terms of developing treatments or vaccines against them. Happy to talk whenever you have a few minutes, today or tomorrow. Best, Alice

PLEASE NOTE NEW PHONE NUMBER
Alice Park
TIME
(alice_park@time.com)
@aliceparkny
Please set up a call.

Hi Dr. Fauci -

I just read your JAMA piece on the importance of preparedness given the new coronavirus.

I'm wondering if you have a moment to discuss the effort, both before and since the latest outbreak. We are working on a Tick Tock of the situation and I think that effort — done before the latest virus emerged — would be a key piece.

Thanks so much -
Michelle
Please handle this. Thanks.

Tony, Emily

All the best,

WK
Wayne C. Koff, PhD
President and CEO
Human Vaccines Project
One Penn Plaza, Suite 6178
New York, NY 10119
Phone: (b)(6)
Email: (b)(6)
Website: www.humanvaccinesproject.org
Dear Dr. Fauci,

Blue Spark Technologies is the inventor of a wearable patient temperature monitoring patch called TempTraq (www.temptraq.healthcare). TempTraq is a soft, comfortable patch worn under the arm that provides a continuous patient temperature feed to a smart device or directly to a hospital’s monitoring station and/or EHR via Bluetooth.

We currently partner with Doctors Without Borders to support their Ebola clinic in Butembo, DRC and Malaria clinics in Tanzania. University of Rochester Medical Center has also begun to use TempTraq in their Malaria clinics in Zambia and Malawi.

Several clinical trials were conducted that show that TempTraq can:

- Accurately monitor patient temperature
- Detect neutropenic fevers in oncology patients up to three hours earlier than the standard of care
- Enable remote patient fever monitoring that can enable earlier discharge for BMT Patients
With the recent Coronavirus outbreak, we were interested in getting your thoughts about the use of TempTraq for those patients that need remote monitoring. I would love to set up a call to discuss further. Please let me know if there is a good time to connect.

Sincerely,
Ruth

Ruth Phillips BSN, MS, OCN, BCMAS
Director, Medical Affairs

https://temptraq.healthcare/
Marc:
Thanks for the note. Am stuck for a while in DC with the coronavirus situation. I will let you know about any future possibility of my coming up there.
Best regards,
Tony

---

Just quoted you on Fox and Friends.
We want to know if you might be interested in coming to NYU to give Grand Rounds sometime over the next several weeks - on this coronavirus and vaccine candidate.
Grand Rounds are Wednesday mornings at 8 AM
It would be a great honor and pleasure to have you here.
We would of course cover all expenses and your fee.
Hope you will consider.
Marc

Sent from my iPhone
On Jan 22, 2020, at 5:52 AM, Fauci, Anthony (NIH/NIAID) [E] <b>(b)(6)</b> wrote:

**[EXTERNAL]**

Marc:
You certainly can quote me.
Best regards,
Tony

From: Siegel, Marc <b>(b)(6)
Sent: Tuesday, January 21, 2020 10:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] <b>(b)(6)
Subject: Re: Question

thanks Tony!

hope I can quote you!

From: Fauci, Anthony (NIH/NIAID) [E] <b>(b)(6)
Sent: Tuesday, January 21, 2020 10:00:21 PM
To: Siegel, Marc
Subject: RE: Question

**[EXTERNAL]**

Marc:
Thanks for the note. We are already working on a vaccine for the 2019 n-CoV. We have the sequence of the virus and are employing an mRNA vaccine platform in collaboration with Moderna Company. We hope to have the candidate in Phase 1 trials within 3 months. You might remember that we actually developed a DNA vaccine for SARS (another coronavirus pathogen) several years ago and brought it through Phase 1 trials showing safety and immunogenicity. We never developed it further since the SARS outbreak was completely stopped by good public health measures. Bottom line is that there is a good chance that over time, we will develop a vaccine for this virus.
Best regards,
Tony

-----Original Message-----
From: Siegel, Marc <b>(b)(6)
Sent: Tuesday, January 21, 2020 4:41 PM
To: Fauci, Anthony (NIH/NIAID) [E] <b>(b)(6)
Subject: Question

Tony
Any chance of a vaccine for this coronavirus?
I believe they were testing one in dogs.
Marc
Sent from my iPhone
From: Fauci, Anthony (NIH/NAID) [E]
Sent: Mon, 27 Jan 2020 03:09:30 +0000
To: Marston, Hilary (NIH/NAID) [E]
Cc: Conrad, Patricia (NIH/NAID) [E]
Subject: RE: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY

OK. Have Steve sit in for us and de-brief us. You do the Moderna meeting.

From: Marston, Hilary (NIH/NAID) [E] <b (6)
Sent: Sunday, January 26, 2020 10:08 PM
To: Fauci, Anthony (NIH/NAID) [E] <b (6)
Subject: Re: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY

It looks like it overlaps with the Moderna meeting. I will participate in whichever you tell me to (of course), but Steve Smith can listen into GPMB (and has been following/meeting with secretariat etc).

From: Anthony Fauci <b (6)
Date: Sunday, January 26, 2020 at 10:01 PM
To: Hilary Marston <b (6)
Subject: FW: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY

Can you listen in on this? It overlaps with an AMA call.

From: GPMB Secretariat <gpmbsecretariat@who.int>
Sent: Friday, January 24, 2020 9:39 AM
To: As Sy Elhadj <b (6); Brundtland Gro Harlem <b (6); Dzau Victor <b (6); Chris Elias <b (6); Farrar Jeremy <b (6); Fauci, Anthony [NIH/NAID] [E] <b (6); Fore Henrietta <b (6); Gao Fu <b (6); Gashumba Diane <b (6); Kaag Sigrid <b (6); Ilona Kickbusch <b (6); Skvortsova Veronika <b (6); Suzuki Yasuhiro <b (6); Vega Morales Jeanette <b (6); Vega Morales Jeanette <b (6); VijayRaghavan <b (6); Krishnaswamy <b (6)
Cc: MAHJOUR, Jaouad <b (6); MINHAS, Raman <b (6); Toomas Palu <b (6); Pate Muhamed <b (6); RYAN, Michael J. <b (6); SCHWARTLANDER, Bernhard F. <b (6); Alex Harris <b (6); Alveberg, Benedikte Louise <b (6); Chiaki NOGUUCHI <b (6); Esved Marja <b (6); Esved Marja <b (6); Esved Marja <b (6); Esved Marja <b (6); Genggrijp Mette <b (6); Julie.HALL <b (6); Kanarek Morgan <b (6); Marston, Hilary (NIH/NAID) [E] <b (6); Oleg Sonin <b (6); Omar Abdi <b (6); Amelie ROUX <b (6); Tore Godal <b (6)
GABEDAVA, Tsira ; ROSS, Alex ; Banks Lynn ; Block Bruce ; Conrad Jane ; Conrad, Patricia [NIH/NIAID] [E] ; Del Sol Dinia ; Diaz Fen ; Elena Kirsanova ; Gahungu Zacharie ; Harikumar M K ; Harikumar M K ; Kabagire Christine ; KITA Yosuke ; Miller de Vega Teresa ; MURIUKI, Hilda Waithimu ; Muzenda Sindiso ; Sarah Belmir ; YU Bai

Subject: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY

Importance: High

Dear Board members,

As many of you, we are concerned about the Novel 2019-Coronavirus outbreak. We believe the Board has a role to play in supporting the response and encouraging countries to step up their preparedness activities, as well as to support WHO in their efforts.

As co-chairs of the GPMB we therefore suggest to hold a teleconference of the Board to discuss the outbreak.

An outcome of the call could be a GPMB statement supporting the response and highlighting crucial preparedness activities that should be undertaken, or other suggestions to be discussed.

We would suggest to hold the teleconference call on Monday 27 January at 1400-1500 Geneva time. This is the only time next week the Co-Chairs are available.

Attached is information for a telephone bridge for the call. We would appreciate it if you could please confirm your participation.

We will share with you shortly a more detailed agenda.

We look forward to hearing from you on this and thank you for your continued engagement.

Kinds regards,

Gro and As